Inhalation Delivery of Psychedelic Drugs via Aerosol Nebulization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering psychedelic medications, particularly through inhalation, face challenges such as narrow therapeutic indices, side effects, and inefficiencies in oral administration due to first-pass metabolism, necessitating the development of controlled delivery systems that bypass liver metabolism and improve bioavailability.
Innovation Solution
The method involves administering psychedelic drugs as aerosols via inhalation using a mixture of nitrous oxide and oxygen, with nitrous oxide acting as a driving gas for nebulization, allowing for precise control of dosage and duration, and using heated helium-oxygen mixtures to enhance delivery to the central nervous system, potentially reducing side effects and improving bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If psychedelic medications are administered orally, then the route of administration is simple and convenient, but first-pass metabolism leads to decreased efficacy and increased toxicity
Solution Approach 1:
The patent uses an aerosol delivery system as an intermediary between the oral route and direct systemic absorption. The aerosolized medication is inhaled through the lungs, where it is absorbed into the bloodstream and bypasses the liver's first-pass metabolism, thereby maintaining efficacy while avoiding toxicity associated with oral administration
Solution Approach 2:
The invention employs pneumatic principles by using inhalation through the respiratory system to deliver the medication. The aerosol is delivered via the pulmonary route, utilizing the lung's vast surface area and rich vasculature for rapid systemic absorption, avoiding gastrointestinal metabolism while maintaining ease of administration
2Reliability
If the therapeutic index is narrow, then precise dose control is required to maximize benefits, but this increases the complexity of the delivery system
Solution Approach 1:
The patent employs dynamic dose adjustment capabilities in the aerosol delivery system, allowing the therapist to modify dosage parameters in real-time based on patient response. The system can adjust particle size, concentration, and delivery duration to optimize therapeutic effect while maintaining manageable device complexity through intuitive controls
Solution Approach 2:
The invention utilizes parameter changes in the aerosol formulation and delivery conditions to achieve precise dose control. By adjusting parameters such as particle aerodynamic diameter, drug concentration in the aerosol, and inhalation timing, the system maximizes therapeutic benefits while keeping the device complexity within acceptable limits
3Reliability
If aerosol therapy is used to deliver psychedelic drugs systemically, then first-pass metabolism is avoided and bioavailability is improved, but the deposition pattern must be precisely controlled
Solution Approach 1:
The patent applies local quality principles by optimizing the aerosol properties for specific lung regions. The aerosol particles are engineered with specific aerodynamic characteristics to ensure appropriate deposition in the pulmonary alveoli, maximizing systemic absorption while controlling the deposition pattern to avoid upper respiratory tract accumulation
Solution Approach 2:
The invention replaces complex mechanical control systems with optimized aerosol physics. By carefully controlling particle size, density, and flow characteristics, the deposition pattern is controlled through physical principles rather than complex mechanical mechanisms, thereby improving bioavailability while minimizing the complexity of precision control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances bioavailability by at least 25% and reduces time to maximum concentration (Tmax) by at least 50% compared to oral delivery, while minimizing side effects, enabling effective treatment of various central nervous system disorders and psychological conditions.
Implementation Method 1
nitrous oxide acts a driving gas for nebulization of the psychedelic drug
Implementation Method 2
using heated helium-oxygen mixtures to enhance delivery to the central nervous system
Implementation Method 3
fast absorption by the massive surface area of the alveolar region, the abundant vasculature and thin air—blood barrier
Data Source
AI summary
Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.